|
1
|
Karpov DS, Goncharenko AV, Usachev EV, Vasina DV, Divisenko EV, Chalenko YM, Pochtovyi AA, Ovchinnikov RS, Makarov VV, Yudin SM, Tkachuk AP, Gushchin VA. A Strategy for the Rapid Development of a Safe Vibrio cholerae Candidate Vaccine Strain. Int J Mol Sci 2021; 22:ijms222111657. [PMID: 34769085 PMCID: PMC8583953 DOI: 10.3390/ijms222111657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 10/25/2021] [Accepted: 10/26/2021] [Indexed: 12/01/2022] Open
Abstract
Approximately 1/6 of humanity is at high risk of experiencing cholera epidemics. The development of effective and safe vaccines against Vibrio cholerae, the primary cause of cholera, is part of the public health measures to prevent cholera epidemics. Natural nontoxigenic V. cholerae isolates represent a source of new genetically improved and relatively safe vaccine strains. However, the genomic engineering of wild-type V. cholerae strains is difficult, and these strains are genetically unstable due to their high homologous recombination activity. We comprehensively characterized two V. cholerae isolates using genome sequencing, bioinformatic analysis, and microscopic, physiological, and biochemical tests. Genetic constructs were Gibson assembled and electrotransformed into V. cholerae. Bacterial colonies were assessed using standard microbiological and immunological techniques. As a result, we created a synthetic chromoprotein-expressing reporter operon. This operon was used to improve the V. cholerae genome engineering approach and monitor the stability of the genetic constructs. Finally, we created a stable candidate V. cholerae vaccine strain bearing a recA deletion and expressing the β-subunit of cholera toxin. Thus, we developed a strategy for the rapid creation of genetically stable and relatively safe candidate vaccine strains. This strategy can be applied not only to V. cholerae but also to other important human bacterial pathogens.
Collapse
Affiliation(s)
- Dmitry S. Karpov
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov str., 32, 119991 Moscow, Russia
- Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.V.G.); (E.V.U.); (D.V.V.); (A.P.T.); (V.A.G.)
- Correspondence: ; Tel.: +7-(499)-135-98-01
| | - Anna V. Goncharenko
- Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.V.G.); (E.V.U.); (D.V.V.); (A.P.T.); (V.A.G.)
| | - Evgenii V. Usachev
- Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.V.G.); (E.V.U.); (D.V.V.); (A.P.T.); (V.A.G.)
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
| | - Daria V. Vasina
- Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.V.G.); (E.V.U.); (D.V.V.); (A.P.T.); (V.A.G.)
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
| | - Elizaveta V. Divisenko
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
| | - Yaroslava M. Chalenko
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
| | - Andrei A. Pochtovyi
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
- Department of Virology, Biological Faculty, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Roman S. Ovchinnikov
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
| | - Valentin V. Makarov
- Centre for Strategic Planning of FMBA of Russia, 119121 Moscow, Russia; (V.V.M.); (S.M.Y.)
| | - Sergei M. Yudin
- Centre for Strategic Planning of FMBA of Russia, 119121 Moscow, Russia; (V.V.M.); (S.M.Y.)
| | - Artem P. Tkachuk
- Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.V.G.); (E.V.U.); (D.V.V.); (A.P.T.); (V.A.G.)
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
| | - Vladimir A. Gushchin
- Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.V.G.); (E.V.U.); (D.V.V.); (A.P.T.); (V.A.G.)
- N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya str., 18, 123098 Moscow, Russia; (E.V.D.); (Y.M.C.); (A.A.P.); (R.S.O.)
- Department of Virology, Biological Faculty, Lomonosov Moscow State University, 119991 Moscow, Russia
| |
Collapse
|
|
2
|
Ragavan ML, Das N. In Vitro Studies on Therapeutic Potential of Probiotic Yeasts Isolated from Various Sources. Curr Microbiol 2020; 77:2821-2830. [PMID: 32591923 DOI: 10.1007/s00284-020-02100-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/18/2020] [Indexed: 01/24/2023]
Abstract
The present study investigates the therapeutic properties of probiotic yeasts viz. Yarrowia lipolytica VIT-MN01, Kluyveromyces lactis VIT-MN02, Lipomyces starkeyi VIT-MN03, Saccharomycopsis fibuligera VIT-MN04 and Brettanomyces custersianus VIT-MN05. The antimutagenic activity of probiotic yeasts against the mutagens viz. Benzo[a]pyrene (B[a]P), and Sodium azide (SA) was tested. S. fibuligera VIT-MN04 showed highest antimutagenicity (75%). Binding ability on the mutagen acridine orange (AO) was tested and L. starkeyi VIT-MN03 was able to bind AO effectively (88%). The probiotic yeasts were treated with the genotoxins viz. 4-Nitroquinoline 1-Oxide (NQO) and Methylnitronitrosoguanidine (MNNG). The prominent changes in UV shift confirmed the reduction in genotoxic activity of S. fibuligera VIT-MN04 and L. starkeyi VIT-MN03, respectively. Significant viability of probiotic yeasts was noted after being exposed to mutagens and genotoxins. The adhesion capacity and anticancer activity were also assessed using Caco-2 and IEC-6 cell lines. Adhesion ability was found to be more in IEC-6 cells and remarkable antiproliferative activity was noted in Caco-2 cells compared to normal cells. Further, antagonistic activity of probiotic yeasts was investigated against S. typhimurium which was found to be more in S. fibuligera VIT-MN04 and L. starkeyi VIT-MN03. The inhibition of α-glucosidase and α-amylase activity confirmed the antidiabetic activity of probiotic yeasts. Antioxidant activity was also tested using standard assays. Therefore, based on the results, it can be concluded that probiotic yeasts can serve as potential therapeutic agents for the prevention and treatment of colon cancer, type 2 diabetes and gastrointestinal infections.
Collapse
Affiliation(s)
- Mangala Lakshmi Ragavan
- Department of Biomedical Sciences, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India
| | - Nilanjana Das
- Department of Biomedical Sciences, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
| |
Collapse
|